Lutris Pharma, a biopharmaceutical company established to improve cancer therapy and patient quality of life, is enrolling patients in a clinical trial to study the effectiveness of a gel (LUT014) to treat acneiform lesions in stage IV (metastatic) colorectal cancer patients.
Acneiform lesions are a common side effect of cancer patients treated with an EGFR inhibitor, such as those found in Cetuximab or Panitumumab. The lesions are an acne-like rash appearing primarily on the face, scalp, chest, and upper back. Up to 80% of patients treated with EGFR inhibitors develop an acneiform rash, usually within the first couple weeks of treatment.
LUT014 is an investigational drug applied as a topical gel. It is being tested for its ability to reduce the severity of EGFR inhibitor-induced acneiform lesions through a phase 2, randomized, double-blind, placebo-controlled efficacy and safety study.
The study is actively enrolling patients who meet the following criteria and others:
- 18 or older and diagnosed with stage IV (metastatic) colorectal cancer
- ECOG performance status of 0-2
- Currently being treated with Cetuximab or Panitumumab
- Grade 2 (moderate) acneiform lesions
- Patients who are on a stable dose of systemic antibiotics for the last 28 days for their acneiform lesions OR subjects who are NOT on systemic antibiotics for the treatment of acneiform lesions
To express your interest in participating in this clinical trial, find the care center and contact closest to you near the bottom of this page: https://clinicaltrials.gov//study/NCT04759664
Learn more about the impact of acneiform lesions in this video from Lutris.
Driven by a commitment to save lives through best practices and innovation in research participation, the group offered collaborative solutions to improve trial design, messaging, access, and navigation, and ultimately, increase participation.
MRTX1133 is a potential first-in-class oral treatment for patients with the KRASG12D colorectal cancer mutation.
A clinical trial out of Memorial Sloan Kettering Cancer Center has set the cancer community abuzz after it showed a 100 percent success rate among the first 14 participants who completed treatment.